Latest / Stock Movers / KB Homes Down, Arm to Sell Its Own Chips, ImmunityBio Plunges
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, Podcasts, Radio News.
- 0:08Speaker 2: The Stock Movers report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: I'm Carol Master along with Tim Stanevik. Let's get to
- 0:18Speaker 1: some stocks on the move this Tuesday. For that, we're
- 0:21Speaker 1: joined by Bloomberg News equities reporter Avalon Parnell. She joins
- 0:24Speaker 1: us here in studio. Let's start with a name that
- 0:27Speaker 1: actually was moving in the aftermarket.
- 0:29Speaker 3: Yes, KB Home, that's ticker KBH slighting now about four percent.
- 0:33Speaker 3: That's after the homebuilder's second quarter forecast trailed estimates basically
- 0:36Speaker 3: across the board. It also reported revenue and home deliveries
- 0:39Speaker 3: for the first quarter that slightly missed expectations. Management did
- 0:43Speaker 3: also mention something that I found interesting, at least in
- 0:46Speaker 3: the release, that they have concerns surrounding the conflict in
- 0:49Speaker 3: the Middle East because it's introduced another layer of uncertainty
- 0:52Speaker 3: for consumers who are already facing several challenges in the
- 0:55Speaker 3: macro environment. Though of course they say that they're definitely
- 0:58Speaker 3: able to weather that storm.
- 0:59Speaker 1: Yes, we'll see right, but this is certainly something on
- 1:03Speaker 1: a couple of different levels that certainly could impact people
- 1:06Speaker 1: in terms of purchasing homes.
- 1:07Speaker 3: Was this the one you forgot to do in your decliners?
- 1:11Speaker 1: Didn't this earning?
- 1:12Speaker 2: Oh?
- 1:12Speaker 3: Yeah, I just came out.
- 1:13Speaker 1: Yeah see, okay, just making sure you know you were
- 1:17Speaker 1: going to do one on the home. No, oh, okay,
- 1:19Speaker 1: I don't know what I'm talking about. Let's just edit
- 1:22Speaker 1: that out, please, everybody. Let's actually keep that in. That
- 1:27Speaker 1: was kind of entertaining.
- 1:28Speaker 3: All right, let's keep going. What about ARM? Yes, ARM
- 1:32Speaker 3: ticker ARM very easy to remember, gaining about six point
- 1:36Speaker 3: six percent postmarket. That's after the semiconductor devices firm said
- 1:39Speaker 3: that it plans to begin selling its own chips for
- 1:41Speaker 3: the first time in a bid for some additional AI sales.
- 1:45Speaker 3: Meadow will be the first major customer, and the chips
- 1:48Speaker 3: will be produced by Taiwan Semiconductor Manufacturing. Also worth noting
- 1:52Speaker 3: that ARM expects those annual cells from the new chip
- 1:54Speaker 3: business to be about fifteen billion dollars within five hours.
- 1:59Speaker 3: The chips are expect to be available now. However, they're
- 2:01Speaker 3: going to begin shipping at the end of this year.
- 2:03Speaker 1: Yeah, I mean, we had a great interview from our
- 2:06Speaker 1: Tom mackenzie talking with the company's CEO. So it's it's interesting.
- 2:10Speaker 1: I mean, this is certainly something we're watching. And yeah,
- 2:13Speaker 1: I mean the whole semiconductor right space. I mean it's
- 2:17Speaker 1: up what about twenty three percent year to date, so
- 2:19Speaker 1: we've definitely seen moved to the upside. Yeah. Check out, well, no,
- 2:22Speaker 1: check out Rene Haas's interview on the Bloomberg terminal. As
- 2:25Speaker 1: Carol mentioned, Tom McKenzie sitting down with him on this Tuesday.
- 2:29Speaker 1: All right, now for something different.
- 2:31Speaker 3: Yes, very different. Immunity bioticker iv RX think about twenty
- 2:35Speaker 3: one percent into the clothes today for its biggest tumble
- 2:38Speaker 3: since twenty twenty four out for as slightly interesting reason.
- 2:41Speaker 3: That's after the FDA issued a warning letter to the
- 2:44Speaker 3: biotech for false and misleading promotion of its bladder cancer
- 2:47Speaker 3: drug and Kativa. At issue is a recent TV ad
- 2:50Speaker 3: for the drug and the firms billionaire executive chairman Patrick
- 2:54Speaker 3: Sun schung rhetoric on the Sean Spicer Show. He said
- 2:59Speaker 3: the drug could treat all cancers, but as I said earlier,
- 3:01Speaker 3: it's actually only approved for a very specific kind of
- 3:05Speaker 3: bladder cancer. Now, the company spokesperson did tell Bloomberg that
- 3:09Speaker 3: they are taking the FDA's concerns very seriously and they
- 3:11Speaker 3: intend to respond within the timeframe. But still worth noting
- 3:14Speaker 3: that that stock remains up nearly two hundred and seventy
- 3:17Speaker 3: five percent this year.
- 3:20Speaker 2: The stock Moover's report from Bloomberg Radio. Check back with
- 3:25Speaker 2: us throughout the day for the latest roundup of companies
- 3:27Speaker 2: making news on Wall Street and for the latest market
- 3:30Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:35Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:38Speaker 2: the Bloomberg Business app.